HFX is an FDA-approved technology and the only paresthesia-free therapy approved by the FDA to treat diabetic neuropathy.
More than 34 million Americans have diabetes, and 20 to 25 percent of people with diabetes develop PDN, painful diabetic neuropathy, according to a May 9 press release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
